不同疾病严重程度的成年哮喘患者的血浆白三烯E4水平

Leukotriene E4 plasma levels in adult asthmatic patients with variable disease severity.

作者信息

Chavis C, van Vyve T, Chanez P, Farce M, Bousquet J, Michel F B, Godard P

机构信息

INSERM U 454, Clinique des Maladias Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France.

出版信息

Allergy. 1997 May;52(5):589-92. doi: 10.1111/j.1398-9995.1997.tb02606.x.

DOI:10.1111/j.1398-9995.1997.tb02606.x

PMID:9201374

Abstract

Cysteinyl leukotrienes (C-LTs) are local inflammatory mediators involved in bronchial asthma. Seventeen asthmatic patients (FEV1 ranging from 41 to 99.8% of predicted values) and 11 healthy subjects were studied. The clinical severity of asthma was assessed by the Aas score. Plasma C-LTs were measured by enzyme immunoassay (EIA) after sample purification by solid-phase extraction (SPE), to investigate whether differences may exist between asthmatic and control subjects and whether leukotriene E4 (LTE4) levels were related to the severity of disease. LT measurements showed that 87.6 +/- 1.2% was recovered as LTE4 and 9.4 +/- 1.3% as LTC4. In asthmatic subjects, LTE4 plasma levels were found to be significantly higher than those in the control group (1.073 +/- 0.133 and 0.53 +/- 0.19 ng/ml of plasma, respectively; P < 0.002). Moreover, there was a significant correlation between LTE4 plasma levels and the Aas clinical score (P < 0.005). These data suggest that plasma LTE4 levels might be used to assess the severity of asthma.

摘要

半胱氨酰白三烯（C-LTs）是参与支气管哮喘的局部炎症介质。对17例哮喘患者（FEV1为预测值的41%至99.8%）和11名健康受试者进行了研究。通过阿斯评分评估哮喘的临床严重程度。在通过固相萃取（SPE）对样品进行纯化后，采用酶免疫测定法（EIA）测量血浆C-LTs，以研究哮喘患者与对照受试者之间是否存在差异，以及白三烯E4（LTE4）水平是否与疾病严重程度相关。LT测量结果显示，回收的LTE4占87.6 +/- 1.2%，LTC4占9.4 +/- 1.3%。在哮喘患者中，发现LTE4血浆水平显著高于对照组（分别为1.073 +/- 0.133和0.53 +/- 0.19 ng/ml血浆；P < 0.002）。此外，LTE4血浆水平与阿斯临床评分之间存在显著相关性（P < 0.005）。这些数据表明，血浆LTE4水平可用于评估哮喘的严重程度。